TKI Therapy in CML: Emerging Treatments, Ensuring Safety
Jointly provided by
Support for this activity has been provided through an educational grant from Pfizer.
Release date: 10/31/2018
Expiration date: 10/31/2019
Estimated time to complete: 1.0 hour
Overview
To optimize outcomes in the treatment of patients with chronic myeloid leukemia (CML), early treatment with the most appropriate first-line tyrosine kinase inhibitor (TKI) is vital. The key to achieving an early and enduring molecular response is the selection of a TKI specifically tailored to the patient’s disease and comorbidity profiles. Mutational resistance to first-generation TKI imatinib and treatment discontinuation because of side effects have spurred the recent development of second- and third-generation TKIs that display different potencies and side-effect profiles.
This Virtual Practice summarizes advances in TKI treatment in the context of disease- and patient-specific characteristics, reviews the most effective methods for monitoring early response and long-term therapeutic outcomes, and assesses the milestones and mutational analyses that indicate when a change in TKI therapy is needed. The activity also compares toxicity profiles of the currently available TKIs and examines how toxicity could interact with a patient’s pre-existing comorbidities and influence adherence and outcomes.
The Virtual Practice includes the following:
- Clinical Callout (located in the Main Conference Room) presents patient vignettes that pause at critical clinical decision points. Your challenge: assess symptoms, risk factors, and medical histories and choose the most appropriate next step from several possible clinical strategies. But be careful: only one option reflects current best practice!
- Hot Seat (located in the Staff Conference Room) is our virtual Q&A with a panel of experts who answer challenging questions on recent advances in CML patient management.
- The Resource Library, which houses downloadable content such as practice tools and patient-directed educational resources.
Faculty
Elias Jabbour, MD—Program Chair
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Michael W. Deininger, MD, PhD
Chief, Division of Hematology/Hematologic Malignancies
Huntsman Cancer Institute
M. M. Wintrobe Professor of Medicine
Senior Director of Transdisciplinary Research
University of Utah
Salt Lake City, Utah
Jerald Patrick Radich, MD
Member, Clinical Research Division
Fred Hutch
Professor of Medicine
University of Washington
Seattle, Washington
Target Audience
This activity has been designed to meet the educational needs of hematologists, medical oncologists, health system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with CML.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize recent treatment advances for CML and their potential implications for clinical practice
- Explain current clinical evidence on treatment goals and monitoring steps for patients with chronic-phase CML receiving TKI therapy
- Select treatment in the frontline setting based on current clinical evidence and disease- and patient-specific characteristics to maximize the likelihood of achieving complete molecular remission/cytogenetic remission
- Recognize differences in the toxicity profile among TKIs and the impact of these differences in tailoring treatment for the individual patient
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and RedMedEd. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure
The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship with a pharmaceutical or equipment company.* Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
*The ACCME defines a commercial interest as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providing clinical service directly to patients to be a commercial interest.
Disclosures are as follows:
Elias Jabbour, MD, has disclosed the following relevant financial relationships:
Contracted Research: AbbVie, Amgen, Novartis, Pfizer, Takeda
Michael W. Deininger, MD, PhD, has disclosed the following relevant financial relationships:
Advisory Board: Ariad, Blueprint, Galena Biopharma, Incyte, Novartis, Pfizer
Consultant: Incyte, Novartis, Pfizer
Contracted Research: Novartis, Pfizer
Jerald Patrick Radich, MD, has disclosed the following relevant financial relationships:
Consultant: Adaptive, Amgen, Novartis, Seattle Genetics
Contracted Research: Novartis
Albert Einstein College of Medicine
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine have no conflict of interest with commercial interests related directly or indirectly to this educational activity.
CME Reviewer
Victor B. Hatcher, PhD
Associate Dean for CME
Professor, Department of Biochemistry
Professor, Department of Medicine
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York
Dr. Hatcher has disclosed no relevant financial relationships.
Peer Reviewer
Amit Verma, MBBS
Professor, Department of Medicine (Oncology)
Professor, Department of Developmental & Molecular Biology
Albert Einstein College of Medicine
Director, Division of Hematology-Oncology
Montefiore Medical Center
Bronx, New York
Dr. Verma has disclosed no relevant financial relationships.
RedMedEd
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Yvette Murley, PhD, Medical Director, has disclosed no relevant financial relationships.
Kristen Petro Slade, Operations Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Albert Einstein College of Medicine, Montefiore Medical Center, RedMedEd, and Pfizer do not recommend the use of any agent outside the labeled indications.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine, Montefiore Medical Center, RedMedEd, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.
If you have questions about this CME activity, please contact Albert Einstein College of Medicine at (718) 920-6674 or cme@montefiore.org.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or education@redmeded.com.
Hardware/Software Requirements
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome, Internet Explorer 9 or higher, or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
Privacy
Albert Einstein College of Medicine and Montefiore Medical Center, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting to the ACCME.
Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx
Copyright
Copyright © 2018 Albert Einstein College of Medicine and RedMedEd. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.